TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01844752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 1% Gel
Description: Twice daily NVN1000 1% Gel for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 4% Gel
Description: Twice daily NVN1000 4% Gel for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Twice daily Vehicle Gel for 12 weeks
Study: NCT03295890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needing
Description: Dry Needling

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry Needing
Description: Dry Needling
Study: NCT01951638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (5 mg)
Description: 5 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (5 mg)
Description: 5 mg BAY1021189 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01340469

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
Study: NCT04304664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness- Based Intervention
Description: Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment.
Study: NCT01767558

Intervention type: OTHER
Group type: OTHER
Intervention: Ablation / MRI
Description: All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit.
Study: NCT03583749

Intervention type: DRUG
Intervention: Subcutaneous (SC) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.

Intervention type: DRUG
Intervention: Subcutaneous (SC) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.

Intervention type: DRUG
Intervention: Subcutaneous (SC) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.

Intervention type: DRUG
Intervention: Intravenous (IV) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.

Intervention type: DRUG
Intervention: Intravenous (IV) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.

Intervention type: DRUG
Intervention: Intravenous (IV) route for antibiotic treatment
Description: Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
Study: NCT04011774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLANI-REV
Description: Cognitive remediation program.
Study: NCT04025034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital decompression with ultrasonic bone removal
Description: Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
Study: NCT04544657

Intervention type: OTHER
Intervention: no intervention
Description: No intervention for enrolled patients

Intervention type: OTHER
Intervention: no intervention
Description: No intervention for enrolled patients
Study: NCT04011774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RELAXATION
Description: Stimulation with no cognitive remediation.
Study: NCT02382068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given via intratympanic injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given via intratympanic injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard of care treatment with the following treatment course criteria:~1. Dose: \> 50 mg/m2~2. Frequency: q3 -q4 weeks~3. Cycles: 7 maximum
Study: NCT01326026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
Study: NCT02276222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 50 mcg BID eFlow (CS) nebulizer
Description: SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva® 18 mcg QD Handihaler
Description: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Study: NCT00838955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
Study: NCT01385072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double matched sibling transplantation
Description: Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS.
Study: NCT03544892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: 60-80 g total carbohydrate per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care diet
Description: \> 150 g total carbohydrate per day
Study: NCT02185625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safe Delivery smartphone application
Description: The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
Study: NCT00765596

Intervention type: OTHER
Intervention: Liquid diet for 3 days
Description: The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
Study: NCT04028986

Intervention type: DRUG
Intervention: Ulipristal Acetate 5 MG Oral Tablet
Description: use of ulipristalacetate OR surgery before fertility treatment
Study: NCT00419822

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 6 Acupuncture visits

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: 6 Acupuncture visits with sham procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient to receive standard care without Acupuncture or Sham Acupuncture.
Description: Standard care
Study: NCT04365582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg day 1 ; 250 mg/day for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg x 3/day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir 200Mg/Ritonavir 50Mg Tab
Description: 400/100 mg (2 tablets) x 2/day for 15 days
Study: NCT00158665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
Description: 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
Study: NCT02136940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMA0076

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00649558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone HCl Tablets 45 mg
Description: 45mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos® Tablets 45 mg
Description: 45mg, single dose fasting
Study: NCT04521855

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires in French on the quality of life, the burden of caregiving and a screening for depressive symptoms, completed during specific interviews.
Study: NCT04549363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.
Study: NCT03360942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCC DBS
Description: Deep Brain Stimulator
Study: NCT03750006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short session HIIT
Description: Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
Study: NCT03736603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIPA Intervention Bundle 1
Description: The PIPA intervention bundle 1 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIPA Intervention Bundle 2
Description: The PIPA intervention bundle 2 includes:~1. Pathway Implementation Toolkit~2. Local Multidisciplinary Champions~3. Audit and Feedback~4. Educational Seminars/Webinars~5. Practice Facilitation~6. Mobile App
Study: NCT00693251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crush technique
Description: Crush technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: provisional T stenting
Description: Provisional T stenting
Study: NCT01093612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: PET images performed on a GE Discovery 16 Ste PET-CT scanner

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: copper Cu 64-DOTA-trastuzumab
Description: 15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Correlative Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies
Study: NCT03901235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: Suspension of mesenchymal stromal cells for intratissular injection
Study: NCT01394458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 % ethanol / 4% sodium citrate catheter locking solution
Description: This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin 1000 u / ml
Description: In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
Study: NCT04771819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWIS
Description: Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWIS
Description: Bilateral experimental blister wounds on each forearm. The wound on one arm is rinsed with experimental solution (SWIS) and the contralateral wound on the other arm is rinsed With Saline as a comparator.
Study: NCT01889511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group - texts
Description: Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes.
Study: NCT01532882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin
Description: tablet, 600mg, PO, 1 tab per day during 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, PO, 1 per day during 28 days
Study: NCT04521959

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restricted and normal aerobic exercise and resistance exercise
Description: Interventions of the same duration and intensity will be applied to two groups.
Study: NCT00871143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT specific for BDD
Description: This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non specific CBT
Description: Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
Study: NCT00678899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24
Description: Implantation with Nucleus Hybrid L24 cochlear implant
Study: NCT00735228

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial pancreas
Description: Artificial endocrine pancreas (NIKKISO Company)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial pancreas
Description: Artificial endocrine pancreas (NIKKISO Company)
Study: NCT02938351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative care
Description: Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
Study: NCT03822962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600Mg Tablet
Description: ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Regimen | Tylenol
Description: Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Regimen | Tylenol
Description: Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
Study: NCT00594633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: donepezil and questionaires
Description: Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
Study: NCT04134767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Linkage
Description: Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overdose Education
Description: Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
Study: NCT04186390

Intervention type: OTHER
Intervention: Simulation training in small bowel capsule endoscopy
Description: Training in the evaluation of small bowel capsule endoscopies including evaluation, diagnostic and treatment in different cases.
Study: NCT05893212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature based facilitated group intervention
Description: The Nature-group programme included learning more about local outdoor areas and nature itself, the biotopes visited were chosen to provide a various nature experience, including forests, farmland, lakes, and seashore. Accompanied by nature guides the group practiced simple sensorial exercises that enhance the contact with nature and its microbiome.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise in group
Description: The Sports-group participated in an exercise programme and met weekly in community sports facilities. Exercise we define as a planned, structured, repetitive, and purposeful form of physical activity that aims for improvement or maintenance of one or more components of physical fitness. The sports programme was planned and executed by professional sports leaders in cooperation with health professionals and included both aerobic and anaerobic exercise as well as team sports, content was planned according to current best practice and considered the participants physical ability.
Study: NCT02576990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion